Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued
Reference number: GID-TA10609
The Department for Health and Social Care has asked NICE to conduct an appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour.
However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for Pexidartinib for treating symptomatic tenosynovial giant cell tumour adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.